Characterization of Vitronectin Effect in 3D Ewing Sarcoma Models: A Digital Microscopic Analysis of Two Cell Lines.

childhood cancer digital quantification extracellular matrix hydrogels

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Sep 2024
Historique:
received: 19 09 2024
accepted: 25 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Ewing sarcoma (ES) is an aggressive bone and soft-tissue pediatric cancer. High vitronectin (VN) expression has been associated with poor prognosis in other cancers, and we aimed to determine the utility of this extracellular matrix glycoprotein as a biomarker of aggressiveness in ES. Silk fibroin plus gelatin-tyramine hydrogels (HGs) were fabricated with and without cross-linked VN and cultivated with A673 and PDX73 ES cell lines for two and three weeks. VN secretion to culture media was assessed using ELISA. Morphometric analysis was applied for phenotypic characterization. VN release to culture media was higher in 3D models than in monolayer cultures, and intracellular, intercellular, and pericluster presence was also observed. A673-HGs showed lower density of clusters but a proportion of larger clusters than PDX73-HGs, which presented low cluster circularity. The cluster density of A673-HGs without added VN was higher than with added VN and slightly lower in the case of PDX73-HGs. Furthermore, a culture time of three weeks provided no benefits in cluster growth compared to two weeks, especially in A673-HGs. These advances in 3D modeling and digital quantification pave the way for future studies in ES and other cancers to deepen understanding about intra- and intercellular heterogeneity and anti-adhesion VN therapies.

Identifiants

pubmed: 39409975
pii: cancers16193347
doi: 10.3390/cancers16193347
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CRIS Contra el Cáncer
ID : 2023/188
Organisme : Instituto de Salud Carlos III
ID : PI20/01107
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00484
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00361
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : FPU20/05344

Auteurs

Amparo López-Carrasco (A)

Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Karina Parra-Haro (K)

Pathology Department, Medical School, University of Valencia, 46010 Valencia, Spain.

Isaac Vieco-Martí (I)

Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Sofía Granados-Aparici (S)

Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Juan Díaz-Martín (J)

Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Instituto de Biomedicina de Sevilla, Department of Pathology, Hospital Universitario Virgen del Rocío, CSIC-Universidad de Sevilla, 41013 Seville, Spain.

Carmen Salguero-Aranda (C)

Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Instituto de Biomedicina de Sevilla, Department of Pathology, Hospital Universitario Virgen del Rocío, CSIC-Universidad de Sevilla, 41013 Seville, Spain.

Delia Acevedo-León (D)

University Hospital Dr. Peset, 46017 Valencia, Spain.

Enrique de Álava (E)

Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Instituto de Biomedicina de Sevilla, Department of Pathology, Hospital Universitario Virgen del Rocío, CSIC-Universidad de Sevilla, 41013 Seville, Spain.
Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009 Seville, Spain.

Samuel Navarro (S)

Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Pathology Department, Medical School, University of Valencia, 46010 Valencia, Spain.

Rosa Noguera (R)

Incliva Biomedical Health Research Institute, 46010 Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Pathology Department, Medical School, University of Valencia, 46010 Valencia, Spain.

Classifications MeSH